The traditional herbal medicinal product Myrrhinil-Intest® is a fixed herbal combination, which is marketed in Germany since 1959 and applied in medical practice for the treatment of gastrointestinal disorders such as functional diarrhea, irritable bowel syndrome and inflammatory bowel disease. It contains myrrh, which is described as the oleo-gum resin from mainly Commiphora molmol Engler (Burseraceae), coffee charcoal, which are the milled roasted to blackening outer seed parts of green dried Coffea Arabica Linné (Rubiaceae) fruits and chamomile flowers - the flower heads of Matricaria recutita Linné (Asteraceae). The clinical effectiveness of Myrrhinil-Intest® for the treatment of various gastrointestinal disorders was demonstrated in several clinical studies and is described in various experience reports, however its pharmacological profile is not fully elucidated. Within the present study the spasmolytic and anti-inflammatory potential of the components myrrh, chamomile and coffee charcoal was investigated. Therefore pharmacological, histological and molecular biological methods were utilised. Spasmolytic activity was characterised using isometric tension measurement with rat isolated small intestinal preparations. Anti-inflammatory potential was assessed with different methods using isolated rat small intestinal preparations and immune cell lines. Inflammation was induced with TNBS and LPS respectively. Additionally, the influence of the herbal components on the gene expression profile of native human macrophages after LPS/IFNγ stimulation was determined by microarray gene expression analysis. Chamomile flower and myrrh exerted spasmolytic effects, whereby the more pronounced spasmolytic effects of myrrh were mediated via calcium channel blockade. Myrrh and chamomile flower exerted anti-inflammatory effects.

The traditional herbal medicinal product Myrrhinil-Intest® is a fixed herbal combination, which is marketed in Germany since 1959 and applied in medical practice for the treatment of gastrointestinal disorders such as functional diarrhea, irritable bowel syndrome and inflammatory bowel disease. It contains myrrh, which is described as the oleo-gum resin from mainly Commiphora molmol Engler (Burseraceae), coffee charcoal, which are the milled roasted to blackening outer seed parts of green dried Coffea Arabica Linné (Rubiaceae) fruits and chamomile flowers - the flower heads of Matricaria recutita Linné (Asteraceae). The clinical effectiveness of Myrrhinil-Intest® for the treatment of various gastrointestinal disorders was demonstrated in several clinical studies and is described in various experience reports, however its pharmacological profile is not fully elucidated. Within the present study the spasmolytic and anti-inflammatory potential of the components myrrh, chamomile and coffee charcoal was investigated. Therefore pharmacological, histological and molecular biological methods were utilised. Spasmolytic activity was characterised using isometric tension measurement with rat isolated small intestinal preparations. Anti-inflammatory potential was assessed with different methods using isolated rat small intestinal preparations and immune cell lines. Inflammation was induced with TNBS and LPS respectively. Additionally, the influence of the herbal components on the gene expression profile of native human macrophages after LPS/IFNγ stimulation was determined by microarray gene expression analysis. Chamomile flower and myrrh exerted spasmolytic effects, whereby the more pronounced spasmolytic effects of myrrh were mediated via calcium channel blockade. Myrrh and chamomile flower exerted anti-inflammatory effects.

The herbal preparation coffee charcoal is produced by over-roasting and milling green dried Coffea arabica L. seeds, and has a long-standing tradition in the treatment of inflammatory and gastrointestinal disorders. Its therapeutic properties are commonly attributed to adsorptive and astringent effects. This insufficiently explains its mode of action, especially when used in the treatment of inflammatory diseases in lower dosages. Our investigations aimed to identify bioactive secondary plant metabolites affecting cytokine-signaling. Thus, a phytochemical analysis of coffee charcoal extract was conducted using HPLC and LC/MS. Trigonelline, neochlorogenic acid, chlorogenic acid, caffeine, cryptochlorogenic acid, feruloylquinic acid isomers, and a caffeoylquinolacton were identified in the extract. Subsequently, the effects of coffee charcoal extract, chlorogenic acid isomers, their metabolite caffeic acid, caffeine, and trigonelline on cytokine (TNF, IL-6, MCP-1) release from LPS-challenged human THP-1 macrophages were examined to evaluate anti-inflammatory activity. Coffee charcoal showed concentration-dependent mild-to-medium inhibitory effects. The chlorogenic acid isomers and caffeic acid inhibited the TNF release, with cryptochlorogenic acid exerting the most distinct effects, as well as decreasing the release of IL-6 and MCP-1. In addition, scanning electron microscopic images provided an impression of the particle constitution, indicating a larger particle size and less structured surface of coffee charcoal in comparison to activated charcoal. In conclusion, our findings underline that beyond adsorptive effects, coffee charcoal exhibits pharmacological properties, which derive from a spectrum of secondary plant metabolites and support the therapeutic use in inflammatory diseases. Chlorogenic acids, particularly cryptochlorogenic acid, appear as pivotal bioactive compounds.